Tue, Mar 3, 2015, 10:15 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Progenics Pharmaceuticals, Inc. Message Board

  • jimturner54321 jimturner54321 Mar 31, 2014 3:14 AM Flag

    Presentation April 6th at American Association for Cancer Research


    Abstract Number: 798
    Presentation Title: Androgen receptor, PI3K/mTOR and PSMA: Exploring and exploiting the interplay between therapeutic targets in prostate cancer
    Presentation Time: Sunday, Apr 06, 2014, 1:00 PM - 5:00 PM
    Location: Hall A-E, Poster Section 33
    Poster Board Number: 12
    Author Block: Jose D. Murga, Wells W. Magargal, II, Sameer M. Moorji, Vincent A. DiPippo, William C. Olson. Progenics Pharmaceuticals, Inc, Tarrytown, NY
    Abstract Body: Introduction: Androgen receptor (AR), the PI3K/mTOR signaling pathway and prostate-specific membrane antigen (PSMA) represent significant potential targets for prostate cancer therapy. The present study examined the cross-regulation and co-targeting of these molecular pathways.
    Methods: Cytotoxicity and the kinetics of antigen expression were evaluated in prostate cancer cell lines (LNCaP and C4-2) that vary according to androgen dependence. Expression of PSMA, prostate-specific antigen (PSA), and AR was evaluated in cells cultured in rapamycin and AR inhibitors. Cells were tested for susceptibility to PI3K/mTOR inhibitors used alone and in combination with PSMA ADC, a fully human PSMA monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE). Potential drug synergy or antagonism was evaluated using the Bliss independence method.
    Results: In androgen-dependent LNCaP cells, rapamycin exerted antiproliferative effects that were accompanied by an increase in AR expression and signaling in the absence of any significant effect on PSMA expression. In androgen-independent C4-2 cells, rapamycin increased AR expression/signaling and PSMA expression in the absence of any significant anti-proliferative effect. AR inhibitors synergized with PSMA ADC in LNCaP and C4-2 cells, but PI3K/mTOR pathway inhibitors synergized with PSMA ADC in C4-2 cells only. More modest synergy was observed by combining non-targeted microtubule inhibitors with inhibitors of AR or mTOR. Compared with rapamycin, GDC0941 (PI3K inhibitor) and MK-2206 (Akt inhibitor), both upstream of mTOR, synergized less strongly with PSMA ADC in C4-2 cells.
    Conclusions: In this study, AR and PI3K/mTOR pathways exhibited cross-regulation impacting PSMA expression. PSMA ADC synergized with AR and mTOR inhibitors via a multimodal mechanism involving increased PSMA expression and disruption of microtubule function. The findings support clinical exploration of regimens combining PSMA-targeted therapies with inhibitors of the AR and/or PI3K/mTOR signaling pathways.

    American Association for Cancer Research
    615 Chestnut St. 17th Floor
    Philadelphia, PA 19106

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.78+0.13(+1.95%)Mar 3 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.